Aimmune Therapeutics Inc logo

AIMT - Aimmune Therapeutics Inc Share Price

$13.98 -0.5  -3.2%

Last Trade - 27/03/20

Sector
Healthcare
Size
Mid Cap
Market Cap £730.0m
Enterprise Value £647.8m
Revenue £n/a
Position in Universe 2155th / 6324
Bullish
Bearish
Unlock AIMT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AIMT Revenue Unlock AIMT Revenue

Net Income

AIMT Net Income Unlock AIMT Revenue

Normalised EPS

AIMT Normalised EPS Unlock AIMT Revenue

PE Ratio Range

AIMT PE Ratio Range Unlock AIMT Revenue

Dividend Yield Range

AIMT Dividend Yield Range Unlock AIMT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AIMT EPS Forecasts Unlock AIMT Revenue
Profile Summary

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated June 24, 2011
Public Since August 6, 2015
No. of Shareholders: 15
No. of Employees: 215
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 65,041,825
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AIMT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AIMT
Upcoming Events for AIMT
Similar to AIMT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.